secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biofrontera Inc. (BFRI)
CIK:        0001858685
Form:       8-K
Filed at:   2024-08-14T23:59:59+00:00
Accession:  0001493152-24-032328
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biofrontera Q2 revenue $7.8M (+34% YoY); net loss narrows to $0.3M from $9.8M
-----------------------------------------------------------------------------

- Q2 2024 total revenues $7.8M, up 34% from $5.8M in Q2 2023; catch-up from lower 1Q sales due to Change Healthcare cyber event.
- Net loss improved to $257K from $9.8M; adjusted EBITDA -$4.7M vs -$7.9M in prior year.
- Cash and equivalents $4.4M at June 30, 2024, up from $1.3M at Dec 31, 2023; raised $8.0M from May 2024 warrant exercises.
- Launched FDA-approved RhodoLED XL lamp in June; shipped first three machines within one week of launch.
- Took control of all US clinical trials for Ameluz on June 1, 2024, under amended license agreement to reduce costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1858685/000149315224032328/0001493152-24-032328-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1858685/000149315224032328/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-032328

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer